Safety issues with bisphosphonate therapy for osteoporosis

Rheumatology (United Kingdom)

Volumn 53, Issue 1, 2014, Pages 19-31

  Suresh, Ernest ^a   Pazianas, Michael ^b   Abrahamsen, Bo ^c,d  

^a Alexandra Hospital (Jurong Health)   (Singapore)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Atrial fibrillation; Atypical femoral fracture; Bisphosphonates; Drug holiday; Oesophageal cancer; Osteonecrosis of jaw; Osteoporosis; Pregnancy; Renal impairment; Safety

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ESOPHAGUS CANCER; EVIDENCE BASED PRACTICE; FEMUR FRACTURE; HEART ATRIUM FIBRILLATION; HUMAN; JAW OSTEONECROSIS; KIDNEY FUNCTION; LACTATION; LOW DRUG DOSE; OSTEOPOROSIS; PATIENT SAFETY; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEVERE RENAL IMPAIRMENT; TREATMENT DURATION;

ATRIAL FIBRILLATION; ATYPICAL FEMORAL FRACTURE; BISPHOSPHONATES; DRUG HOLIDAY; OESOPHAGEAL CANCER; OSTEONECROSIS OF JAW; OSTEOPOROSIS; PREGNANCY; RENAL IMPAIRMENT; SAFETY;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; TREATMENT OUTCOME;

EID: 84890913241     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket236     Document Type: Review

References (133)

1. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
2. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
3. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis: a randomised controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) group. JAMA 1999;282:1344-52.
4. Reginster JY, Minne H, Sorensen O et al. Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.
5. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40.
6. Black DM, Delmas PD, Eastell R et al. Once-yearly zolendronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
7. Lyles KW, Colon-Emeric CS, Magaziner JS et al. Zolendronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809.
8. Delmas PD, Recker RR, Chesnut CH III et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792-8.
9. Adachi JD, Saag KG, Delmas PD et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11.
10. Wallach S, Cohen S, Reid DM et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-85.
11. Orwoll E, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-10.
12. Boonen S, Reginster JY, Kaufman JM et al. Fracture risk and zolendronic acid therapy in men with osteoporosis. N Engl J Med 2012;367:1714-23.
13. McClung M, Harris ST, Miller PD et al. Bisphosphonate therapy for osteoporosis: benefits, risks and drug holiday. Am J Med 2013;126:13-20.
14. Nevitt MC, Thompson DE, Black DM et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med 2000;160:77-85.
15. Bolland MJ, Grey AB, Gamble GD et al. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 2010;95:1174-81.
16. Dell R, Greene D. Is osteoporosis disease management cost effective? Curr Osteoporos Rep 2010;8:49-55.
17. Marx RE. Pamidronate (Aredia) and zolendronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7.
18. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253-4.
19. Ruggiero SL, Mehrotra B, Rosenberg TJ et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
20. Khosla S, Burr D, Cauley J et al. Bisphophonateassociated osteonecrosis of jaw: report of a task force of the American Society of Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91.
21. Pazianas M. Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst 2011;103:232-40.
22. Christodoulou C, Pervena A, Klouvas G et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009;76:209-11.
23. Almazrooa SA, Woo SB. Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review. J Am Dent Assoc 2009;140:864-75.
24. Epstein MS, Ephros HD, Epstein JB. Review of current literature and implications of RANKL inhibitors for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; Aug 15 [Epub ahead of print].
25. Estilo CL, Fornier M, Farooki M et al. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008;26:4037-8.
26. Brunello A, Saia G, Bedogni A et al. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 2009;44:173-5.
27. Zervas K, Verrou E, Teleioudis Z et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134:620-3.
28. Badros A, Weikel D, Salama A et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-52.
29. Dimopoulos MA, Kastritis E, Anagnostopoulos A et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zolendronic acid. Haematologica 2006;91:968-71.
30. Walter C, Grotz KA, Kunkel M et al. Prevalence of bisphosphonate associated osteonecrosis of jaw within the field of osteonecrosis. Support Care Cancer 2007;15:197-202.
31. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61.
32. Bilezikian JP. Osteonecrosis of the jaw- do bisphosphonates pose a risk? N Engl J Med 2006;355:2278-81.
33. Khan AA, Sandor GK, Dore E et al. Bisphosphonate associated osteonecrosis of jaw. J Rheumatol 2009;36:478-90.
34. Chamizo Carmona E, Gallego Flores A, Loza Santamaria E et al. Systematic literature review of bisphosphonates and osteonecrosis of jaw in patients with osteoporosis. Rheumatol Clin 2013;9:172-7.
35. Edwards BJ, Hellstein JW, Jacobsen PL et al. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2008;139:1674-7.
36. Ruggiero SL, Dodson TB, Assael LA et al.; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009;67(5 Suppl):2-12.
37. Subramanian G, Cohen HV, Quek SY. A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential role in its resolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112:703-5.
38. Narvaez J, Narvaez JA, Gomez-Vaquero C et al. Lack of response to teriparatide therapy for bisphosphonateassociated osteonecrosis of the jaw. Osteoporos Int 2013;24:731-3.
39. Aviles RJ, Martin DO, Apperson-Hansen C et al. Inflammation as a risk factor for Atrial Fibrillation. Circulation 2003;108:3006-10.
40. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007;356:1895-6 (letter).
41. Lyles KW, Colon-Emeric CS, Magaziner JS et al. Zolendronic acid and clinical fractures and mortality after hip fractures. N Engl J Med 2007;357:1799-809.
42. Karam R, Camm J, McClung M. Yearly zolendronic acid in postmenopausal osteoporosis. N Engl J Med 2007;357:712-3; author reply 714-5.
43. Heckbert SR, Li G, Cummings SR et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008;168:826-31.
44. Sorenson HT, Christensen S, Mehnert F et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008;336:813-6.
45. Pazianas M, Cooper C, Wang Y et al. Atrial fibrillation and the use of oral bisphosphonates. Ther Clin Risk Manag 2011;7:131-44.
46. Grosso A, Douglas I, Hingorani A et al. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS One 2009;4:e4720.
47. Bunch TJ, Anderson JL, May HT et al. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 2009;103:824-8.
48. Abrahamsen B, Eiken P, Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 2009;265:581-92.
49. Kim SY, Kim MJ, Cadarette SM et al. Bisphosphonates and risk of atrial fibrillation: a meta-analysis. Arthritis Res Ther 2010;12:R30.
50. Barrett-Connor E, Swern AS, Hustad CM et al. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporos Int 2012;23:233-45.
51. Mak A, Cheung MW, Ho RC et al. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomised controlled trials and observational studies. BMC Musculoskelet Disord 2009;10:113.
52. Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 2009;32:219-28.
53. Bhuriya R, Singh M, Molnar J et al. Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 2010;142:213-7.
54. Tanko LB, Christiansen C, Cox DA et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005;20:1912-20.
55. Majumdar SR. Oral bisphosphonates and atrial fibrillation. BMJ 2008;336:784-5.
56. Pazianas M, Compston J, Huang CL. Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res 2010;25:2-10.
57. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:89-90.
58. Abraham SC, Cruz-Correa M, Lee YA et al. Alendronateassociated esophageal injury: pathological and endoscopic features. Mod Pathol 1999;12:1152-7.
59. Ribeiro A, DeVault KR, Wolfe JT III et al. Alendronateassociated oesophagitis. Gastrointest Endosc 1998;47:525-8.
60. Robins HI, Holen KD. More on reports of oesophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:1790.
61. Abrahamsen B, Pazianas M, Eiken P et al. Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res 2012;27:679-86.
62. Green J, Czanner G, Reeves G et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010;341:c4444.
63. Vestergaard P. Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis. Calcif Tissue Int 2011;89:434-41.
64. Cardwell CR, Abnet CC, Cantwell MM et al. Exposure to oral bisphosphonates and risk of oesophageal cancer. JAMA 2010;304:657-63.
65. Nguyen DM, Schwartz J, Richardson P et al. Oral bisphosphonate prescriptions and the risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus. Dig Dis Sci 2010;55:3404-7.
66. Chen YM, Chen DY, Chen LK et al. Alendronate and risk of oesophageal cancer: a nation-wide population based study in Taiwan. J Am Geriatr Soc 2011;59:2379-81.
67. Chiang CH, Huang CC, Chan WL et al. Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: a nationwide study. J Bone Miner Res 2012;27:1951-8.
68. Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:1789; author reply 1791-2.
69. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data. BMJ 2013;346:f114.
70. Sun K, Liu JM, Sun HX et al. Bisphosphonate treatment and risk of oesophageal cancer: a meta-analysis of observational studies. Osteoporosis Int 2013;24:279-86.
71. Dixon WG, Solomon DH. Bisphosphonates and oesophageal cancer-a pathway through the confusion. Nat Rev Rheumatol 2011;7:369-72.
72. Odvina CV, Zerwekh JE, Rao DS et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301.
73. Iwata K, Allen MR, Phipps R et al. Microcrack initiation occurs more easily in vertebrae from beagles treated with alendronate than with risedronate. Bone 2006;38(Suppl):42.
74. Tan SC, Koh SBJ, Goh SK et al. Atypical femoral stress fractures in bisphosphonate-free patients. Osteoporos Int 2011;22:2211-2.
75. Shane E, Burr D, Ebeling PR et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-94.
76. Park-Wyllie LY, Mamdani MM, Juurlink DN. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011;305:783-9.
77. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011;364:1728-37.
78. Meier RP, Perneger TV, Stern R et al. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012;172:930-6.
79. Nieves JW, Bilezikian JP, Lane JM et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2010;21:399-408.
80. Wang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res 2011;26:553-60.
81. Kwek EB, Goh SK, Koh JS et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy. Injury 2008;39:224-31.
82. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008;358:1304-6.
83. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 2010;47:169-80.
84. Black DM, Kelly MP, Genant HK et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010;362:1761-71.
85. Feldstein AC, Black D, Perrin N et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 2012;27:977-86.
86. Rydholm A. Highly different risk estimates for atypical femoral fracture with use of bisphosphonates-debate must be allowed! Acta Orthop 2012;83:319-20.
87. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009;24:1095-102.
88. Abrahamsen B, Eiken P, Eastell R et al. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010;95:5258-65.
89. Kim SY, Schneeweiss S, Katz JN et al. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res 2011;26:993-1001.
90. Poole KE, Compston JE. Bisphosphonates in the treatment of osteoporosis. BMJ 2012; e3211.
91. Black DM, Schwartz AV, Ensrud KE et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38.
92. Black DM, Reid IR, Boonen S et al. The effect of 3 versus 6 years of zolendronic acid treatment of osteoporosis: a randomised extension to the HORIZONPivotal Fracture Trial (PFT). J Bone Miner Res 2012;27:243-54.
93. Watts NB, Chines A, Olszynski WP et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008;19:365-72.
94. Black DM, Bauer DC, Schwartz AV et al. Continuing bisphosphonate treatment for osteoporosis-for whom and for how long? N Engl J Med 2012;366:2051-3.
95. Curtis JR, Westfall AO, Cheng H et al. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 2008;19:1613-20.
96. Gallagher AM, Rietbrock S, Olson M et al. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 2008;23:1569-75.
97. Schwartz AV, Bauer DC, Cummings SR et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010;25:976-82.
98. Klawansky S, Komaroff E, Cavanaugh PF Jr et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporosis Int 2003;14:570-6.
99. Miller PD, Roux C, Boonen S et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005;20:2105-15.
100. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
101. Jamal SA, Bauer DC, Ensrud KE et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007;22:503-8.
102. Miller PD. Fragility fractures in chronic kidney disease: an opinion-based approach. Cleve Clin J Med 2010;76:715-23.
103. Wetmore JB, Benet LZ, Kleinstuck D et al. Effects of short-term alendronate on bone mineral density in haemodialysis patients. Nephrology 2005;10:393-9.
104. Hosking D. Management of osteoporosis in patients with renal disease. Osteoporos Rev 2008;16:1-5.
105. Stathopoulos IP, Liakou CG, Katsalira A et al. The use of bisphosphonates in women prior to or during pregnancy and lactation. Hormones (Athens) 2011;10:280-91.
106. Patlas N, Golomb G, Yaffe P et al. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralisation in rats. Teratology 1999;60:68-73.
107. Minsker DH, Manson JM, Peter CP. Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol 1993;121:217-23.
108. Ornoy A, Wajnberg R, Diav-Citrin O. The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 2006;22:578-9.
109. Levy S, Fayez I, Taguchi N et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone 2009;44:428-30.
110. Dunlop DJ, Soukop M, McEwan HP. Antenatal administration of aminopropylidene diphosphonate. Ann Rheum Dis 1990;49:995.
111. Illidge TM, Hussey M, Godden CW. Malignant hypercalcemia in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol (R Coll Radiol) 1996;8:257-8.
112. Losada I, Sartori L, Di Gianantonio E et al. Bisphosphonates in patients with autoimmune rheumatic diseases: can they be used in women of child bearing age? Autoimmun Rev 2010;9:547-52.
113. Siminoski K, Fitzgerald AA, Flesch G et al. Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding. J Bone Miner Res 2000;15:2052-5.
114. Hassen-Zrour S, Korbaa W, Bejia I et al. Maternal and fetal outcome after long-term bisphosphonate exposure before conception. Osteoporos Int 2010;21:709-10.
115. Peris P, Torra M, Olivares V et al. Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. Bone 2011;49:706-9.
116. Tanko LB, McClung MR, Schimmer RC et al. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. Bone 2003;32:421-6.
117. Rosen CJ, Hochberg MC, Bonnick SL et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005;20:141-51.
118. Reid IR, Gamble GD, Mesenbrink P et al. Characterization of and risk factors for the acute-phase response after zolendronic acid. J Clin Endocrinol Metab 2010;95:4380-7.
119. Wark J, Recknor C, Ryabitseva O et al. Treatment with acetaminophen/paracetomol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zolendronic acid 5 mg. Bone 2010;46(Suppl 1):S33.
120. Bock O, Boerst H, Thomasius FE et al. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact 2007;7:144-8.
121. Hemmati I, Wade J, Kelsall J. Risedronate-associated scleritis: a case report and review of the literature. Clin Rheumatol 2012;31:1403-5.
122. Fraunfelder FW, Fraunfelder FT. Bisphosphonates and ocular inflammation. N Engl J Med 2003;348:1187-8.
123. Kaur H, Uy C, Kelly J et al. Orbital inflammatory disease in a patient treated with zolendronate. Endocr Pract 2011;17:e101-3.
124. Pazianas M, Clark EM, Eiken PA et al. Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications-cohort analysis using a nationwide prescription database. J Bone Miner Res 2012; Oct 8 [Epub ahead of print].
125. Chang JT, Green L, Beitz J. Renal failure with the use of zolendronic acid. N Engl J Med 2003;349:1676-9.
126. Boonen S, Sellmeyer DE, Lippuner K et al. Renal safety of annual zolendronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008;74:641-8.
127. Peter R, Mishra V, Fraser WD. Severe hypocalcemia after being given intravenous bisphosphonate. BMJ 2004;328:335-6.
128. Yanik B, Turkay C, Atalar H. Hepatotoxicity induced by alendronate therapy. Osteoporos Int 2007;18:829-31.
129. Polyzos SA, Kountouras J, Anastasilakis AD et al. Zolendronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone. Osteoporos Int 2011;22:363-7.
130. Kanis JA, Hans D, Cooper C et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int 2011;22:2395-411.
131. Ringe JD, Doherty JG. Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int 2010;30:863-9.
132. Dell RM, Adams AL, Greene DF et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012;27:2544-50.
133. Liberman UA, Weiss SR, Broll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43.